Clifton Mo

Oncologist in Boston.

[Clifton Mo @CliftonCraigMo]

@Myeloma_Doc Exciting findings, Bob. So linvo after mezi (intact target plus reinvigorated T-cells) may be a promising strategy post-Tec?

[Clifton Mo @CliftonCraigMo]

@adamssperling 🤦🏻‍♂️

[Clifton Mo @CliftonCraigMo]

@OmarNadeemMD @IreneGhobrial @szusmani @MSKCancerCenter @DanaFarber @MalinHultcrantz @CarlynRTanMD @ShoMidha Cue 8 Mile theme song. Can’t wait!

[Dana-Farber News @DanaFarberNews]

Congratulations to Dana-Farber’s @IreneGhobrial on being chosen as the recipient of the prestigious William Dameshek Prize from The American Society of Hematology (@ASH_hematology)! https://t.co/046sGkw0M2

[Adam Sperling @adamssperling]

Excited that our new paper is now online @BloodJournal. https://t.co/g985ymMa74

This has been a wonderful collaborative effort between our teams @DFCINews and @MDAndersonNews. #mmsm #leusm

[The Lancet Haematology @TheLancetHaem]

Now OF: A multicentre cohort study used MALDI-TOF mass spectrometry to screen for monoclonal gammopathies in serum from 7622 individuals. A high prevalence of monoclonal gammopathies, including lower-level monoclonal gammopathies, was detected. #mmsm
https://t.co/iZOXlURlwc

[Shonali Midha, M.D. @ShoMidha]

Check out the @DanaFarber Advances in Hematologic Malignancies 2022 Winter Issue!! Features by @adamssperling @TheBianchiLab @sarahcud @OmarNadeemMD Catherine Marinac, PhD @IreneGhobrial & co-editor @CliftonCraigMo, and faculty spotlight of @DrMHB1 #mmsm
https://t.co/Hn4lTnILkG

[Promise Study @PromiseStudy]

A great video related to our #IMPACTStudy, #COVID19, & #MultipleMyeloma. @cliftonmo @CliftonCraigMo discusses COVID-19 vaccines/treatments & their impact on MM patients at the @DanaFarber 2022 MM Patient Education Symposium. #mmsm #myelomaresearch
https://t.co/iGRk4PLFk5

[Clifton Mo @CliftonCraigMo]

@ranjitbindra @YaleMed @YaleRadOnc @YaleCancer

[Clifton Mo @CliftonCraigMo]

@szusmani @mskcc @FredsTeam Congrats Saad!

[Nature Cancer @NatureCancer]

🌟"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple #myeloma" by @IreneGhobrial &Co @NatureCancer

Find it at:
https://t.co/qO3bqZfy7t

#11F #WomenInScience #WomenAndGirlsInScience @UN_Women

[Adam Sperling @adamssperling]

Excited that our work led by @mksamur is now out in @NatureComms on biallelic loss of BCMA as a resistance mechanism to CAR T-cells in multiple. https://t.co/PIKQRMUyYz

[Clifton Mo @CliftonCraigMo]

Fascinating study by @ColemanLindsley @DanaFarber showing that donor-derived CH can actually improve outcomes in allotransplant. Possible implications for non-transplant immunotherapies in MM? #ASH20 #mmsm

[Clifton Mo @CliftonCraigMo]

@Shri_doctor It was my pleasure, glad you enjoyed!

[Clifton Mo @CliftonCraigMo]

The plot thickens.. #mmsm @IreneGhobrial @DanaFarber

[. @IreneGhobrial]

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant | Nature Communications https://t.co/HRJ7RmrzzF

[Clifton Mo @CliftonCraigMo]

@MariwallaDerm 😂

[Clifton Mo @CliftonCraigMo]

@Dax_x98 Lol

[Dr. Minoo Battiwalla @DrBattiwalla]

Make sure you get that name. The Name of the Dog | NEJM https://t.co/7XZrRHH9yP

[Judith Trotman @JudithTrotman1]

Note: exclusion of patients with prior cancer from Clinical Trials to treat current cancer not evidence based. Time to relax this criterion. https://t.co/v1rrv8HOqO

[Graham Collins @graham74GC]

Rochiewski et al - DA-EPOCH-R in Burkitt. Outstanding results in an older patient group. Represents new standard of care. #ASH17 #lymsm